Abstract
Targeting of T or NK cells to tumor cells by bispecific antibodies as a possible way of targeting cancer cells has gained increasing interest in the past few years. We treated 31 patients with malignant glioma by means of local adoptive transfer of lymphokine-activated killer (LAK) cells coupled with bispecific antibodies (anti-CD3Xanti-glioma) as an adjuvant therapy. Approximately 50% of the patients treated with this specific targeting therapy (STT) remain alive at 3-year follow-up, and 40% of the patients are free from recurrence. The effectiveness of this therapy is confirmed by serial computed tomography (CT) scans, which revealed disappearance of remnant tumors in some patients. In addition, histological specimens obtained by the use of CT-guided stereotactic biopsy from the lesions showed marked necrosis and degeneration after STT. However, patients presenting with recurrent glioma were relatively resistant to STT. This is because a hyaline membrane formed on the surface of glioma that may interfere with lymphocyte tracking into the tumor from the operative and histological findings. Five patients developed microbial infection, but 4 cases were treated successfully with the use of antimicrobial drugs. No neurological deterioration was observed after STT. Taken together, STT can produce higher response rates in malignant glioma patients than those achieved with LAK cells only or with other conventional treatments, and might be one of the most promising adjuvant therapies for other types of cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Quigley MR, Maroon JC (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29:385–389
Jacobs SK, Wilson DJ, Kornblith PL (1986) Interleukin-2 and autologous lymphokineactivated killer cells in the treatment of malignant glioma. J Neurosurg 64:743–749
Merchant RE, Merchant LE, Cook SHS (1989) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725–732
Rosenberg SA, Lotze MT (1986) Cancer Immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4:681–709
Neuwelt EA, Clark K, Kirkpatrick JB (1978) Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol 4:307–312
Young H, Kaplan A, Regelson W (1977) Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme. A preliminary report. Cancer 40:1037–1044
Fontana A, Hengertner H, de Tribolet (1984) Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2-mediated effect. J Immunol 132:1837–1844
Grimm EA, Ramsey KM, Mazumder A (1983) Lymphokine activated killer cell phenomenon. J Exp Med 157:884–897
Barba D, Saris CS, Holder C (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182
Nitta T, Sato K, Okumura K (1990) Induction of cytotoxicity in human T cells coated with anti-gliomaXanti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72:476–481
Perez P, Hoffman RW, Shaw S (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354–356
Van Lier RAW, Boot JHA, de Groot ER (1987) Induction of T cell proliferation with antiCD3 switch variant monoclonal antibodies. Eur J Immunol 17:1599–1604
Nitta T, Yagita H, Azuma T (1989) Bispecific F(ab’) 2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Eur J Immunol 19:1437–1441
Nitta T, Sato K, Yagita H (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1:368–376
The Committee of Brain Tumor Registry of Japan (1992) Brain Tumor Registry of Japan. Neurol Med Chir (Tokyo) 32:385–547
Van Dijk JS, Warnaar SO, Van Eedenburg JDH (1989) Induction of tumor-cell lysis by bispecific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43:344–349
Nitta T, Nakata M, Yagita H (1991) Interleukin-2 activated T cells express CD 16 and are triggered to target cell lysis by anti-CD 16 linked to anti-target heteroantibody. Immunol Lett 28:31–38
Titus JA, Garrido MA, Hecht TT (1987) Human T cells targeted with anti-T3 cross-linked to anti-tumor antibody prevent tumor growth in nude mice. J Immunol 138:4018–4022
Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628–631
Jacobs SK, Wilson DJ, Kornblith PL (1986) In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64:114–117
Pupa SM, Canevari S, Fontanelli R (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int J Cancer 42:455–459
Watne K, Hannisdal E, Nome O (1992) Combined intra-arterial an systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery 30:223–227
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Japan
About this paper
Cite this paper
Hishii, M., Nitta, T., Ebato, M., Okumura, K., Sato, K. (1996). Clinical Results of Specific Targeting Therapy Against Patients with Malignant Glioma. In: Nagai, M. (eds) Brain Tumor. Springer, Tokyo. https://doi.org/10.1007/978-4-431-66887-9_37
Download citation
DOI: https://doi.org/10.1007/978-4-431-66887-9_37
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-66889-3
Online ISBN: 978-4-431-66887-9
eBook Packages: Springer Book Archive